Regulation of CEACAM Family Members by IBD-Associated Triggers in Intestinal Epithelial Cells, Their Correlation to

Gonzalo Saiz-Gonzalo1,2,3, Naomi Hanrahan1,2,3, Valerio Rossini1

  • 1APC Microbiome Ireland, University College Cork, National University of Ireland, Cork, Ireland.

Frontiers in Immunology
|August 16, 2021
PubMed

Insights

Carcinoembryonic antigen cellular adhesion molecules (CEACAMs) are altered in inflammatory bowel diseases (IBD). This study found CEACAM expression changes in IBD patients and identified triggers and drugs regulating CEACAMs in intestinal cells, revealing their role in IBD pathogenesis.

Area of Science:

  • Gastroenterology and Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Carcinoembryonic antigen cellular adhesion molecules (CEACAMs) are expressed in intestinal epithelial cells.
  • CEACAM1, -3, -5, -6, -7 alterations are noted in colon cancer and inflammatory bowel diseases (IBD).
  • The specific role of CEACAMs in IBD pathogenesis remains unclear.

Purpose of the Study:

  • To correlate CEACAM expression levels with inflammation severity in pediatric and adult IBD.
  • To investigate the regulation of CEACAMs by IBD-associated factors in intestinal epithelial cells.
  • To examine the effect of IBD drugs on CEACAM expression.

Main Methods:

  • Analysis of CEACAM expression in colon biopsies from pediatric Crohn's disease and adult ulcerative colitis patients.
  • In vitro studies using human intestinal epithelial cell lines (C2BBe1/HT29) treated with cytokines, bacteria, metabolites, emulsifiers, and IBD drugs.
  • Quantitative assessment of CEACAM RNA and protein expression, and IL-8 secretion.

Main Results:

  • Increased CEACAM3, -5, -6 expression in pediatric CD and active adult UC; reduced CEACAM5 in adult CD.
  • Pro-inflammatory triggers and emulsifiers induced CEACAMs, while SCFAs reduced them.
  • IBD drugs, especially Tofacitinib, suppressed cytokine-induced CEACAM expression and IL-8 secretion.

Conclusions:

  • CEACAMs are differentially regulated by various IBD-associated triggers in intestinal epithelial cells.
  • CEACAM expression patterns correlate with IBD inflammation severity.
  • CEACAMs play a significant role in the pathogenesis of inflammatory bowel diseases.

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
432
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
473
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
461
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
574
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
566
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
262